1. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events (MACE) by 20% (hazard ratio [HR], 0.80) in patients with overweight or obesity but without diabetes.
2. The cardioprotective effect was largely independent of baseline adiposity or weight loss, suggesting mechanisms beyond simple fat reduction.
3. At 20 weeks, semaglutide led to a 6.4% weight loss and 5.0-cm decrease in waist circumference, compared with 0.8% and 1.1 cm in the placebo group. 
4. Every 5-cm smaller waist circumference correlated with a 4% lower MACE risk (HR, 0.96), accounting for about one-third of the total cardiovascular benefit.
5. Semaglutide offers a dual benefit for cardiovascular and metabolic risk reduction in patients with obesity and established atherosclerotic cardiovascular disease, supporting its consideration beyond glycemic control.

Source: The Lancet